Dr. Guo is an Associate Professor of Community Medicine and Cancer Center as well as the Program Assistant Director of West Virginia Clinical and Translational Science Institute (WVCTSI) for Biomedical Informatics. She received her Bachelor of Science ...
Publications/Editing: With a strong background in bioinformatics, Dr. Guo has a total of 42 peer-reviewed journal publications, 11 papers in IEEE or ACM conference proceedings, two invited book chapters, and 18 abstracts published in conferences, including the American Association for Cancer Research and Society of Toxicology. Her work on breast cancer prognostic gene signatures was featured on the cover of Clinical Cancer Research (April 2007). Her work on lung cancer prognostic biomarkers received 2007 NIOSH Nomination for the CDC Excellence in Science Awards (CHARLES C. SHEPARD SCIENCE AWARDS). Her work on developing a lung cancer prognostic model using an epidemiology approach won the 2nd Place Poster Award in the 4th CCTS Scientific Meeting and 5th Annual Appalachian Health Summit in 2013.
Dr. Guo serves on Editorial Board of PLOS ONE, Cancer Informatics, Oncology Letters, and Journal of Thoracic Disease. She serves on the Executive Committee of International Society for Translational Medicine since 2011.
Dr. Guo is a tenured Professor of Occupational and Environmental Health Sciences in the School of Public Health and Cancer Center as well as Co-Chair of Biomedical Informatics at West Virginia Clinical and Translational Science Institute (WVCTSI). She holds a B.S. in Biochemistry and Molecular Biology from Beijing University and a PhD in Computer and Information Science from West Virginia University.
Prior to joining WVU, Dr. Guo served as an Assistant Professor in Computer Science at the University of Southern Mississippi. Her teaching interests include bioinformatics, gene microarray profiling, and personalized medicine. Her research interests include algorithm development for bioinformatics and systems biology and clinical applications of gene and/or protein expression-based prognostic models for personalized cancer treatment. her groups has utilized computational toxicogenomics for risk assessment of nanoparticles for occupational and environmental health protection.
Dr. Guo currently has R01 funding from the National Institute of Environmental Health Sciences to systematically assess toxicity effects of nanoparticles in human lung diseases.
Dr. Guo has served as a member of the National Institute of Health (NIH) Study Section and Special Emphasis Panels since 2009. She has also served as Chair and/or a reviewer of DOD scientific review panels.
Dr. Guo She has been PI of multiple NIH grants with a total of $5.8M since 2005. She was awarded a R01 grant from the National Institute of Health (NIH)/National Library of Medicine in 2008, with a priority score of 129, ranking in the top 4.7 percentile. In August 2009, she was awarded an NIH ARRA stimulus grant to advance translational research. In 2012, she was awarded two NIH grants with a total amount of $2.1 M to investigate nanoparticles and lung disease, including fibrosis and lung cancer. She also served as Project Director of several institutional NIH CoBRE grants, including West Virginia IDeA-CTR.
Her biomarker research has resulted in five pending patents and has been featured by numerous national and international news organizations, including International Innovation, Science Works for US, Newswise, and Fox Business News.
Sara Crile Allen and James Frederick Allen Lung Cancer
The traditional prognostic factors for cancer are imperfect. In part, they lack the information about the biological diversity of cancer and have not reflected the complexity of molecular mechanism of the diseases. In addition, they focus on predicting for populations instead of for individuals. Recent advances in the knowledge of human genomics and proteomics, as well as bioinformatics, have revolutionized the ways in which researchers are able to identify molecular signatures of cancer recurrence and metastases.
Genome-wide studies will guide hypothesis-driven experimentation and aid clinical decision-making. Bioinformatics is the key to identifying new disease biomarkers and making accurate predictions in molecular diagnosis and prognosis. My research interests include applying bioinformatics methods to clinical research, specifically, to the identification of novel biomarkers for the diagnosis, prognosis, and therapeutics prediction of human diseases.
Furthermore, we will employ genomic and proteomic analysis of clinical specimens to validate the biomarkers identified in genome-wide association studies. We are also interested in constructing genome-wide co-expression networks and gene regulation networks. Identifying gene products within one or a few specific pathways could potentially enhance the prognostic value and reveal therapeutic targets for intervention.
Grants and Research
Dr. Guo was awarded an R01 grant from the National Institute of Health (NIH)/National Library of Medicine in 2008, with a priority score of 129, ranking in the top 4.7 percentile. In August 2009, she was awarded an NIH ARRA stimulus grant to advance translational research. Her biomarker research has resulted in five pending patents and has been featured by numerous national and international news organizations, including International Innovation, Science Works for US, Newswise, and Fox Business News.